Medicine
Tascenso ODT 0.25 mg orally disintegrating tablet
Tascenso ODT 0.25 mg orally disintegrating tablet is a prescription medicine containing Fingolimod lauryl for oral use, marketed by Cycle Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store in sealed blister pack.
Key facts
- Active ingredient (INN)
- Fingolimod lauryl
- Brand
- Tascenso ODT
- Strength
- 0.25 mg
- Dosage form
- Orally disintegrating tablet
- Route
- Oral
- Packs
- 3 blister pack
- Marketing authorisation holder
- Cycle Pharmaceuticals
- Manufacturer
- Cycle Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store in sealed blister pack.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 1 February 2023
- Identifiers
- RxCUI 2610295, 2610302, 2626383 +1DailyMed set ID bf8e7f89-ea09-43c7-a7eb-e44724350721NDC 70709-062Application NDA214962
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 3 blister pack in 1 carton / 10 tablet, orally disintegrating in 1 blister pack | 70709-062-30 | Cycle Pharmaceuticals | 1 February 2023 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 23 December 2021 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Fingolimod lauryl
Clinical summary
Fingolimod lauryl is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, among other approved uses. MedsAcross supplies Fingolimod lauryl for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Fingolimod laurylFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- TASCENSO ODT prescribing information (Cycle Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Tascenso ODT 0.25 mg orally disintegrating tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.